EGFR and breast cancer: In support of the concept that doxazosin sensitizes cancer cells to EGFR-TKI, Hui et al. reported that doxazosin enhanced gefitinib-induced apoptosis in breast cancer cells by inhibiting EGFR through a different mechanism to that described in the present study [25].